Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.GLYC · Entity 5255 | SVP Finance, CFO | June 18, 2024 | June 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date June 18, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,643 |
Reported balance
After 2024-06-18 transaction · row 1
1 source rowRow 1 · 2024-06-18 · Purchase · Acquired 17,500 · Balance 70,643 F1: The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2453 to $0.2478 per share, with a weighted average purchase price of $0.2477 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2453 to $0.2478 per share, with a weighted average purchase price of $0.2477 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2024 Filed Jun 20, 2024 20:15 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | PurchaseCommon Stock | 17,500 | $0.25 | $4,334.75 |
DisclosureSEC source: 0001415889-24-017623 · form4-06202024_040634.xml · nonDerivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,643 F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2453 to $0.2478 per share, with a weighted average purchase price of $0.2477 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:05 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001209191-24-001738 · doc4.xml · derivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-01-11 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| May 17, 2023 Filed May 18, 2023 20:27 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 3,700 | $1.95 | $7,215.00 |
DisclosureSEC source: 0001209191-23-030636 · doc4.xml · nonDerivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,143 F1 · kind: The sales reported on this Form 4 were effected to satisfy tax withholding obligations in connection with the settlement of restricted stock units as part of a "sell to cover" transaction and do not represent discretionary trades by the reporting person. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 21:08 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 246,300 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-23-004228 · doc4.xml · derivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,300 Underlying: Common Stock · 246,300 shares Expires 2033-01-18 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 19, 2024 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 21:13 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | PurchaseCommon Stock | 20,000 | $1.06 | $21,200.00 |
DisclosureSEC source: 0001209191-22-056576 · doc4.xml · nonDerivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,843 F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.03 to $1.15 per share, with a weighted average purchase price of $1.06 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 22:03 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 2,917 | $1.09 | $3,179.53 |
DisclosureSEC source: 0001209191-22-017963 · doc4.xml · nonDerivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,843 F1 · kind: The sales reported on this Form 4 were effected to satisfy tax withholding obligations in connection with the settlement of restricted stock units as part of a "sell to cover" transaction and do not represent discretionary trades by the reporting person. F2 · price: The common stock was sold by the reporting person in a series of open market transactions on the transaction date with a volume weighted average sale price of $1.09. The range of sales prices for the transactions reported was $1.09 to $1.11 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 21, 2022 Filed Jan 26, 2022 01:59 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 47,700 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-22-004882 · doc4.xml · derivative · entry 2 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,700 Underlying: Common Stock · 47,700 shares Expires 2032-01-20 F2 · derivative.exercise_date: 50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 21, 2022 Filed Jan 26, 2022 01:59 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 164,700 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-22-004882 · doc4.xml · derivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,700 Underlying: Common Stock · 164,700 shares Expires 2032-01-20 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:06 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001209191-21-004847 · doc4.xml · derivative · entry 2 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2031-01-19 F3 · derivative.exercise_date: 25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:06 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantCommon Stock | 34,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004847 · doc4.xml · nonDerivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,760 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: 25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:00 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,260 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-20-064018 · doc4.xml · derivative · entry 2 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,260 shares Expires 2021-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:00 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | Exercise / conversionCommon Stock | 5,260 | $1.12 | $5,891.20 |
DisclosureSEC source: 0001209191-20-064018 · doc4.xml · nonDerivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 21:20 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001209191-20-004824 · doc4.xml · derivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-01-21 F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 22, 2021 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 23:18 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $10.59 | $0.00 |
DisclosureSEC source: 0001209191-19-004821 · doc4.xml · derivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-01-16 F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 17, 2020 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 21:54 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,260 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-18-037288 · doc4.xml · derivative · entry 3 Hahn Brian M. · CIK 0001589711 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,260 Underlying: Common Stock · 5,260 shares Expires 2021-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 21:54 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 19,345 | $18.04 | $348,983.80 |
DisclosureSEC source: 0001209191-18-037288 · doc4.xml · nonDerivative · entry 2 Hahn Brian M. · CIK 0001589711 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.80 to $18.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 21:54 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | Exercise / conversionCommon Stock | 5,260 | $1.12 | $5,891.20 |
DisclosureSEC source: 0001209191-18-037288 · doc4.xml · nonDerivative · entry 1 Hahn Brian M. · CIK 0001589711 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 21:02 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $20.03 | $0.00 |
DisclosureSEC source: 0001209191-18-003389 · doc4.xml · derivative · entry 1 Hahn Brian M. · CIK 0001589711 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-01-09 F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 10, 2019 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 13:51 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001209191-17-001650 · doc4.xml · derivative · entry 1 Hahn Brian M. · CIK 0001589711 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 4, 2018 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.